Literature DB >> 18390493

Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome.

Ted J Kaptchuk1, John M Kelley, Lisa A Conboy, Roger B Davis, Catherine E Kerr, Eric E Jacobson, Irving Kirsch, Rosa N Schyner, Bong Hyun Nam, Long T Nguyen, Min Park, Andrea L Rivers, Claire McManus, Efi Kokkotou, Douglas A Drossman, Peter Goldman, Anthony J Lembo.   

Abstract

OBJECTIVE: To investigate whether placebo effects can experimentally be separated into the response to three components-assessment and observation, a therapeutic ritual (placebo treatment), and a supportive patient-practitioner relationship-and then progressively combined to produce incremental clinical improvement in patients with irritable bowel syndrome. To assess the relative magnitude of these components.
DESIGN: A six week single blind three arm randomised controlled trial.
SETTING: Academic medical centre. PARTICIPANTS: 262 adults (76% women), mean (SD) age 39 (14), diagnosed by Rome II criteria for and with a score of > or =150 on the symptom severity scale.
INTERVENTIONS: For three weeks either waiting list (observation), placebo acupuncture alone ("limited"), or placebo acupuncture with a patient-practitioner relationship augmented by warmth, attention, and confidence ("augmented"). At three weeks, half of the patients were randomly assigned to continue in their originally assigned group for an additional three weeks. MAIN OUTCOME MEASURES: Global improvement scale (range 1-7), adequate relief of symptoms, symptom severity score, and quality of life.
RESULTS: At three weeks, scores on the global improvement scale were 3.8 (SD 1.0) v 4.3 (SD 1.4) v 5.0 (SD 1.3) for waiting list versus "limited" versus "augmented," respectively (P<0.001 for trend). The proportion of patients reporting adequate relief showed a similar pattern: 28% on waiting list, 44% in limited group, and 62% in augmented group (P<0.001 for trend). The same trend in response existed in symptom severity score (30 (63) v 42 (67) v 82 (89), P<0.001) and quality of life (3.6 (8.1) v 4.1 (9.4) v 9.3 (14.0), P<0.001). All pairwise comparisons between augmented and limited patient-practitioner relationship were significant: global improvement scale (P<0.001), adequate relief of symptoms (P<0.001), symptom severity score (P=0.007), quality of life (P=0.01). Results were similar at six week follow-up.
CONCLUSION: Factors contributing to the placebo effect can be progressively combined in a manner resembling a graded dose escalation of component parts. Non-specific effects can produce statistically and clinically significant outcomes and the patient-practitioner relationship is the most robust component. TRIAL REGISTRATION: Clinical Trials NCT00065403.

Entities:  

Mesh:

Year:  2008        PMID: 18390493      PMCID: PMC2364862          DOI: 10.1136/bmj.39524.439618.25

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  31 in total

Review 1.  What are the main methodological problems in the estimation of placebo effects?

Authors:  Asbjørn Hróbjartsson
Journal:  J Clin Epidemiol       Date:  2002-05       Impact factor: 6.437

Review 2.  The placebo effect in alternative medicine: can the performance of a healing ritual have clinical significance?

Authors:  Ted J Kaptchuk
Journal:  Ann Intern Med       Date:  2002-06-04       Impact factor: 25.391

Review 3.  Expectations and associations that heal: Immunomodulatory placebo effects and its neurobiology.

Authors:  Gustavo Pacheco-López; Harald Engler; Maj-Britt Niemi; Manfred Schedlowski
Journal:  Brain Behav Immun       Date:  2006-08-02       Impact factor: 7.217

Review 4.  The power of context: reconceptualizing the placebo effect.

Authors:  Franklin G Miller; Ted J Kaptchuk
Journal:  J R Soc Med       Date:  2008-05       Impact factor: 5.344

5.  A course of instruction for women with irritable bowel syndrome.

Authors:  Mariette Bengtsson; Kerstin Ulander; Elisabet Bergh Börgdal; Ann-Christine Christensson; Bodil Ohlsson
Journal:  Patient Educ Couns       Date:  2005-08-10

6.  Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.

Authors:  T Lembo; R A Wright; B Bagby; C Decker; S Gordon; P Jhingran; E Carter
Journal:  Am J Gastroenterol       Date:  2001-09       Impact factor: 10.864

Review 7.  Functional bowel disorders.

Authors:  George F Longstreth; W Grant Thompson; William D Chey; Lesley A Houghton; Fermin Mearin; Robin C Spiller
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

8.  A signal detection theory analysis of the placebo effect.

Authors:  Lorraine G Allan; Shepard Siegel
Journal:  Eval Health Prof       Date:  2002-12       Impact factor: 2.651

9.  A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation.

Authors:  J Novick; P Miner; R Krause; K Glebas; H Bliesath; G Ligozio; P Rüegg; M Lefkowitz
Journal:  Aliment Pharmacol Ther       Date:  2002-11       Impact factor: 8.171

Review 10.  Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints.

Authors:  Michael Camilleri; Allen W Mangel; Sheri E Fehnel; Douglas A Drossman; Emeran A Mayer; Nicholas J Talley
Journal:  Clin Gastroenterol Hepatol       Date:  2007-04-11       Impact factor: 11.382

View more
  316 in total

1.  Reevaluating the placebo effect in medical practice.

Authors:  Luana Colloca; Wayne B Jonas; John Killen; Franklin G Miller; David Shurtleff
Journal:  Z Psychol       Date:  2014

2.  Treatment expectations and preferences as predictors of outcome of acupuncture for chronic back pain.

Authors:  Karen J Sherman; Daniel C Cherkin; Laura Ichikawa; Andrew L Avins; Kristin Delaney; William E Barlow; Partap S Khalsa; Richard A Deyo
Journal:  Spine (Phila Pa 1976)       Date:  2010-07-01       Impact factor: 3.468

Review 3.  [Placebo responders in randomized controlled drug trials of fibromyalgia syndrome : Systematic review and meta-analysis].

Authors:  W Häuser; E Bartram-Wunn; C Bartram; T R Tölle
Journal:  Schmerz       Date:  2011-12       Impact factor: 1.107

4.  Placebo response to manual therapy: something out of nothing?

Authors:  Joel E Bialosky; Mark D Bishop; Steven Z George; Michael E Robinson
Journal:  J Man Manip Ther       Date:  2011-02

5.  The placebo phenomenon: implications for the ethics of shared decision-making.

Authors:  Howard Brody; Luana Colloca; Franklin G Miller
Journal:  J Gen Intern Med       Date:  2012-01-19       Impact factor: 5.128

6.  Is bigger better? An argument for very low starting doses.

Authors:  James P McCormack; G Michael Allan; Adil S Virani
Journal:  CMAJ       Date:  2010-10-04       Impact factor: 8.262

7.  Directly observed antidepressant medication treatment and HIV outcomes among homeless and marginally housed HIV-positive adults: a randomized controlled trial.

Authors:  Alexander C Tsai; Dan H Karasic; Gwendolyn P Hammer; Edwin D Charlebois; Kathy Ragland; Andrew R Moss; James L Sorensen; James W Dilley; David R Bangsberg
Journal:  Am J Public Health       Date:  2012-06-21       Impact factor: 9.308

8.  A randomized controlled trial of acupuncture for osteoarthritis of the knee: effects of patient-provider communication.

Authors:  Maria E Suarez-Almazor; Carol Looney; Yanfang Liu; Vanessa Cox; Kenneth Pietz; Donald M Marcus; Richard L Street
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-09       Impact factor: 4.794

9.  Comparison of Electroacupuncture and Mild-Warm Moxibustion on Brain-Gut Function in Patients with Constipation-Predominant Irritable Bowel Syndrome: A Randomized Controlled Trial.

Authors:  Ji-Meng Zhao; Jin-Hua Lu; Xiao-Jun Yin; Lu-Yi Wu; Chun-Hui Bao; Xing-Kui Chen; Yue-Hua Chen; Wei-Jun Tang; Xiao-Ming Jin; Huan-Gan Wu; Yin Shi
Journal:  Chin J Integr Med       Date:  2018-05-11       Impact factor: 1.978

10.  It's all in your head: reinforcing the placebo response with tDCS.

Authors:  H M Schambra; M Bikson; T D Wager; M F DosSantos; A F DaSilva
Journal:  Brain Stimul       Date:  2014-04-15       Impact factor: 8.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.